Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
deals
2
×
life sciences
national blog main
san francisco blog main
abbvie
adeno-associated virus
alexandria venture investments
allergan
altitude life science ventures
alzheimer's disease
american society of gene and cell therapy
arch venture partners
boston
boxer capital
clinical trials
crispr
cynthia collins
dravet syndrome
ed kaye
editas medicine
encoded therapeutics
gene editing
gene therapy
generation bio
hemophilia
illumina
illumina ventures
leber congenital amaurosis type 10
matrix capital management
menlo ventures
michelle robertson
national top stories
new york blog main
new york top stories
parkinson's disease
rare diseases
regulatory elements
What
gene
2
×
treatment
2
×
abbvie
alliance
biotech
crude
cutting
despite
edge
editas
editing
effects
encoded
exits
experimental
genetic
help
illumina’s
lasting
limited
limits
long
medicine
medicines
nabs
pact
partnership
progress
promising
pruning
push
remains
research
returning
rights
single
terminated
therapy
therapy’s
Language
unset
Current search:
deals
×
gene
×
treatment
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
